Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akeso, Inc. ( (HK:9926) ) just unveiled an update.
Akeso, Inc. reported a 37.75% increase in revenue for the first half of 2025, reaching RMB1,411.5 million, driven by a 49.20% rise in commercial sales. Despite the revenue growth, the company experienced a loss of RMB588.3 million, attributed to increased equity investment losses in Summit Therapeutics, higher R&D expenses, and elevated equity incentive costs.
The most recent analyst rating on (HK:9926) stock is a Hold with a HK$158.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
More about Akeso, Inc.
Akeso, Inc. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on commercial sales and license income, with a significant emphasis on research and development activities.
Average Trading Volume: 12,430,594
Technical Sentiment Signal: Buy
Current Market Cap: HK$152.1B
For a thorough assessment of 9926 stock, go to TipRanks’ Stock Analysis page.